BioNTech's Low Valuation, Many Shots On Goal Make It A Buy

46888 ther N H carmengabriela The shares of German pharmaceutical firm BioNTech (NASDAQ:BNTX) have rallied about 13% in the last two days. The gains could have been sparked by the success of Summit Therapeutics' (SMMT) bispecific antibody, ivonescimab, in a Phase III trial involving previously untreated patients with locally advanced or metastatic positive PD-L1 non-small cell lung cancer (NSCLC). Since BioNTech licensed a similar antibody last November from China-based biotech firm Biotheus, some investors ...